LXRX vs. GERN
LXRX (Lexicon Pharmaceuticals, Inc.) and GERN (Geron Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, LXRX returned -18.68%/yr vs -8.94%/yr for GERN. At a 0.35 correlation, their price movements are largely independent.
Performance
LXRX vs. GERN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LXRX achieves a 60.87% return, which is significantly higher than GERN's -12.12% return. Over the past 10 years, LXRX has underperformed GERN with an annualized return of -18.68%, while GERN has yielded a comparatively higher -8.94% annualized return.
LXRX
- 1D
- -2.12%
- 1M
- 15.62%
- YTD
- 60.87%
- 6M
- 32.14%
- 1Y
- 192.72%
- 3Y*
- -12.32%
- 5Y*
- -16.06%
- 10Y*
- -18.68%
GERN
- 1D
- -0.85%
- 1M
- -26.11%
- YTD
- -12.12%
- 6M
- -8.66%
- 1Y
- -26.11%
- 3Y*
- -31.44%
- 5Y*
- -3.55%
- 10Y*
- -8.94%
LXRX vs. GERN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LXRX Lexicon Pharmaceuticals, Inc. | 60.87% | 55.72% | -51.73% | -19.90% | -51.52% | 15.20% | -17.59% | -37.50% | -32.79% | -28.56% |
GERN Geron Corporation | -12.12% | -62.71% | 67.77% | -12.81% | 98.36% | -23.27% | 16.91% | 36.00% | -44.44% | -13.04% |
Correlation
The correlation between LXRX and GERN is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.38 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Apr 10, 2000 | 0.35 |
Fundamentals
LXRX:
$740.44M
GERN:
$776.48M
LXRX:
-$0.07
GERN:
-$0.10
LXRX:
9.90
GERN:
3.95
LXRX:
3.65
GERN:
3.39
LXRX:
$69.64M
GERN:
$196.12M
LXRX:
$69.00M
GERN:
$119.67M
LXRX:
-$20.38M
GERN:
-$40.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LXRX vs. GERN — Risk / Return Rank
LXRX
GERN
LXRX vs. GERN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LXRX | GERN | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.26 | -0.42 | +2.68 |
Sortino ratioReturn per unit of downside risk | 2.87 | -0.25 | +3.12 |
Omega ratioGain probability vs. loss probability | 1.34 | 0.97 | +0.37 |
Calmar ratioReturn relative to maximum drawdown | 5.69 | -0.65 | +6.34 |
Martin ratioReturn relative to average drawdown | 12.51 | -1.29 | +13.79 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LXRX | GERN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.26 | -0.42 | +2.68 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.16 | -0.04 | -0.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.19 | -0.11 | -0.08 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.17 | -0.07 | -0.10 |
Drawdowns
LXRX vs. GERN - Drawdown Comparison
The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum GERN drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for LXRX and GERN.
Loading charts...
Drawdown Indicators
| LXRX | GERN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -98.73% | -1.18% |
Max Drawdown (1Y)Largest decline over 1 year | -34.09% | -40.51% | +6.42% |
Max Drawdown (3Y)Largest decline over 3 years | -91.83% | -78.98% | -12.85% |
Max Drawdown (5Y)Largest decline over 5 years | -95.25% | -78.98% | -16.27% |
Max Drawdown (10Y)Largest decline over 10 years | -98.48% | -86.09% | -12.39% |
Current DrawdownCurrent decline from peak | -99.44% | -98.34% | -1.10% |
Average DrawdownAverage peak-to-trough decline | -93.20% | -86.15% | -7.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.48% | 20.30% | -4.82% |
Volatility
LXRX vs. GERN - Volatility Comparison
Lexicon Pharmaceuticals, Inc. (LXRX) has a higher volatility of 29.25% compared to Geron Corporation (GERN) at 15.09%. This indicates that LXRX's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LXRX | GERN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.25% | 15.09% | +14.16% |
Volatility (6M)Calculated over the trailing 6-month period | 58.59% | 46.90% | +11.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 85.81% | 63.74% | +22.07% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 98.26% | 82.38% | +15.88% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 97.22% | 78.08% | +19.14% |
Dividends
LXRX vs. GERN - Dividend Comparison
Neither LXRX nor GERN has paid dividends to shareholders.
Financials
LXRX vs. GERN - Financials Comparison
This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LXRX vs. GERN - Profitability Comparison
LXRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lexicon Pharmaceuticals, Inc. reported a gross profit of 20.99M and revenue of 21.10M. Therefore, the gross margin over that period was 99.5%.
GERN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported a gross profit of 0.00 and revenue of 51.84M. Therefore, the gross margin over that period was 0.0%.
LXRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lexicon Pharmaceuticals, Inc. reported an operating income of -996.00K and revenue of 21.10M, resulting in an operating margin of -4.7%.
GERN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported an operating income of 158.00K and revenue of 51.84M, resulting in an operating margin of 0.3%.
LXRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lexicon Pharmaceuticals, Inc. reported a net income of -1.04M and revenue of 21.10M, resulting in a net margin of -4.9%.
GERN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported a net income of -3.64M and revenue of 51.84M, resulting in a net margin of -7.0%.
Frequently Asked Questions
LXRX and GERN have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LXRX has higher volatility (29.25%) compared to GERN (15.09%). In terms of maximum drawdown, LXRX dropped -99.91% vs GERN's -98.73%.
LXRX currently has the higher Sharpe Ratio (2.26 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LXRX and GERN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer